Skip to main content
GutCited

Saccharomyces boulardii için Antibiotic-Associated Diarrhea (AAD)

A

Multiple meta-analyses show S. boulardii reduces AAD risk by 47-53% (RR 0.47). Most studied probiotic for AAD prevention with consistent positive results across antibiotic classes.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dsaccharomyces\u002Dboulardii\u0026condition\u003Dantibiotic\u002Dassociated\u002Ddiarrhea'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

Sonuç

Multiple meta-analyses show S. boulardii reduces AAD risk by 47-53% (RR 0.47). Most studied probiotic for AAD prevention with consistent positive results across antibiotic classes.

Key Study Findings

Observational Study n=279
Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …
Dose: None vs: None Outcome: Probiotic prescribing habits of Italian PCPs Etki: L. rhamnosus GG used by 91.8% None

Popülasyon: Italian primary care pediatricians

Review
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Dose: None vs: None Outcome: None Etki: None None

Popülasyon: Pediatric population

Review
Intestinal Dysbiosis: Exploring Definition, Associated Symptoms, and Perspectives for a Comprehensive Understanding - a Scoping …
Dose: None vs: None Outcome: None Etki: None None

Popülasyon: scoping review of intestinal dysbiosis definition, symptoms, and probiotic adjuvant therapy in adults and children

Other
Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …
Dose: None vs: None Outcome: Clinical guideline recommendations for pediatric GI Etki: None None

Popülasyon: Pediatric patients with GI disorders

Review
Clostridioides difficile Infections: Prevention and Treatment Strategies.
Dose: None vs: None Outcome: C. difficile infection treatment outcomes Etki: None None

Popülasyon: Patients with C. difficile infection

Randomized Controlled Trial n=47 1 weeks
[A prospective randomized controlled study on probiotics for the prevention of antibiotic-associated diarrhea in infants …
Dose: None vs: Control Outcome: Gut microbiota composition Etki: None P<0.017

Popülasyon: Children

Key Statistics

25

Çalışmalar

5000

Katılımcılar

Positive

A

Derece

Referenced Papers

Advances in experimental … 2019 17 atıf
The American journal … 2018 46 atıf
Journal of pediatric … 2016 233 atıf
Digestive diseases (Basel, … 2016 37 atıf
The Cochrane database … 2015 233 atıf
Journal of clinical … 2015 35 atıf
Journal of clinical … 2011 432 atıf
Journal for specialists … 2010 22 atıf
American journal of … 2010
European journal of … 2009 91 atıf
Current opinion in … 2009 82 atıf
Advances in biochemical … 2008 535 atıf
American family physician 2008
The Journal of … 2007 265 atıf
International journal of … 2000 181 atıf
Clinical infectious diseases … 1998 346 atıf

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Yaygın Kullanılan Dozajlar

general:
250-500 mg/day (equivalent to 5-10 billion CFU)
aadprevention:
500 mg/day (start with antibiotic, continue 7 days after)
cdiffprevention:
500 mg twice daily as adjunct to standard therapy
travelersdiarrhea:
250-500 mg/day starting 5 days before travel

Üst sınır: Well-tolerated up to 1,000 mg/day in clinical trials

Araştırmalarda İncelenen Dozajlar

Dozaj Süre Etki N
None -- Mixed 279
None -- Mixed --
None -- Positive --
None -- Positive --
None -- Positive --
None 1 weeks Positive 47
None 20 weeks Positive 564
None -- Positive --

En iyi alım zamanı: Can be taken with or without food; space 2 hours from antifungals

Safety & Side Effects

Bildirilen Yan Etkiler

  • Mild gas and bloating
  • Rare: fungemia in critically ill patients with central venous catheters
  • Thirst (yeast may increase water requirements)
  • Very rare: potential environmental contamination risk in ICU settings

Bilinen Etkileşimler

  • Antifungal medications (may kill S. boulardii, reducing effectiveness)
  • Monoamine oxidase inhibitors (S. boulardii contains tyramine)
  • Immunosuppressants (theoretical risk of fungemia in immunocompromised patients)

Tolere edilebilir üst alım: Well-tolerated up to 1,000 mg/day in clinical trials

Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.

Frequently Asked Questions

Does Saccharomyces boulardii help with Antibiotic-Associated Diarrhea (AAD)?
Based on 25 studies with 5,000 participants, there is strong evidence from multiple clinical trials that Saccharomyces boulardii may support Antibiotic-Associated Diarrhea (AAD) management. Our evidence grade is A (Strong Evidence).
How much Saccharomyces boulardii should I take for Antibiotic-Associated Diarrhea (AAD)?
Studies have used various dosages. A commonly studied range is 250-500 mg/day (equivalent to 5-10 billion CFU). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Saccharomyces boulardii?
Reported side effects may include Mild gas and bloating, Rare: fungemia in critically ill patients with central venous catheters, Thirst (yeast may increase water requirements), Very rare: potential environmental contamination risk in ICU settings. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Saccharomyces boulardii and Antibiotic-Associated Diarrhea (AAD)?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 25 peer-reviewed studies with 5,000 total participants. The overall direction of effect is positive.

Related Evidence

Şu durum için diğer içerikler: Antibiotic-Associated Diarrhea (AAD)

Saccharomyces boulardii diğer sağlık durumları için

FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.